Massive typhoid vaccine trial aims to curb fever in india
NCT ID NCT05500482
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large study tested a typhoid conjugate vaccine called TyphiBEV in over 72,000 people aged 1 to 30 years in Vellore, India. The goal was to see if the vaccine reduces the number of confirmed typhoid fever cases in vaccinated communities compared to unvaccinated ones. The trial is now complete, and results will show how well the vaccine works in a real-world, high-burden setting.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Typhoid conjugate vaccine (TyphiBEV)
- What this could lead to
- If successful, this vaccine could significantly reduce typhoid fever in high-burden areas, potentially saving lives and lowering healthcare costs.
- What could go wrong
- This is a completed Phase 4 trial, so results are available, but real-world effectiveness may vary. The vaccine may not work equally in all populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
72,400 people
The number who actually took part.
- Started
-
May 2023
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 30 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Consent * For adults, 18 years and over - they must be willing and competent to provide informed consent * For those aged under 18 years, the parent/guardian is willing and competent to provide informed consent, and if the participant is 11 to 18 years of age, informed assent will also be sought, * Age: * Between 1 and 30 years (i.e., up to 29 years 364 days) at time of recruitment into the surveillance * Currently living within the study catchment area with no plans to leave the study area in the next 24 months Exclusion Criteria: * For fever surveillance o Medical reasons that prevent the participant from complying with study requirements including follow up and testing during illness * For vaccination * Has received a typhoid vaccine in the previous three years * Is known to have an allergy to any vaccine component * Nursing mothers, Pregnancy or planning pregnancy around vaccination * Receipt of any other vaccine in the past 30 days (temporary exclusion) * Febrile illness in the 24 hours before vaccination (temporary exclusion)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Typhoid fever are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Christian Medical College Vellore
Vellore, Tamil Nadu, 632002, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.